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Abstract
Background: Monocytes and macrophages express an extensive repertoire of G Protein-Coupled
Receptors (GPCRs) that regulate inflammation and immunity. In this study we performed a
systematic micro-array analysis of GPCR expression in primary mouse macrophages to identify
family members that are either enriched in macrophages compared to a panel of other cell types,
or are regulated by an inflammatory stimulus, the bacterial product lipopolysaccharide (LPS).
Results: Several members of the P2RY family had striking expression patterns in macrophages;
P2ry6 mRNA was essentially expressed in a macrophage-specific fashion, whilst P2ry1 and P2ry5
mRNA levels were strongly down-regulated by LPS. Expression of several other GPCRs was either
restricted to macrophages (e.g. Gpr84) or to both macrophages and neural tissues (e.g. P2ry12,
Gpr85). The GPCR repertoire expressed by bone marrow-derived macrophages and thioglycollate-
elicited peritoneal macrophages had some commonality, but there were also several GPCRs
preferentially expressed by either cell population.
Conclusion: The constitutive or regulated expression in macrophages of several GPCRs identified
in this study has not previously been described. Future studies on such GPCRs and their agonists
are likely to provide important insights into macrophage biology, as well as novel inflammatory
pathways that could be future targets for drug discovery.
Background
Macrophages are key cellular mediators of acute and
chronic inflammation. They can be defined on the basis of
morphology, function (e.g. non-specific uptake of parti-
cles) and expression of specific cell surface markers (e.g.
EMR1 that is detected by the F4/80 antibody). EMR1
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macrophages express a diverse repertoire of other GPCRs
[2]. A large number of GPCRs are yet to be deorphanized
and hence, there is great potential for this family in both
the discovery of gene function and in drug development.
In this study we performed a systematic micro-array anal-
ysis of GPCR expression in primary mouse macrophages
and identified family members that are either enriched in
macrophages compared to a panel of other cell types, or
are regulated by the pro-inflammatory stimulus, bacterial
LPS. Some of these GPCRs are likely to provide future tar-
gets for drug discovery in inflammatory disease settings.
Results
Constitutive GPCR expression in mouse macrophages
Micro-array expression profiling across a panel of mouse
and human tissues has enabled detailed analysis of tissue-
specific gene expression [3]. In this study, we analyzed the
constitutive and regulated expression of GPCRs in macro-
phages by interrogating a more detailed micro-array data-
set of 91 murine cell types and tissues [3,4]. This data,
available through NCBIs Gene Expression Omnibus ([5]
accession number GSE10246), can also be used to probe
gene expression profiles for an extensive array of other cell
types.
The cell and tissue panel included two of the most com-
monly used primary mouse macrophage models; bone
marrow-derived macrophages (BMM) and thioglycollate-
elicited peritoneal macrophages (TEPM), as well as micro-
glia (a resident tissue macrophage population of the
brain) and the widely utilized macrophage-like cell line,
RAW264. We analyzed the expression patterns of all
GPCRs as defined by the International Union of Basic and
Clinical Pharmacology [6,7]. We then compared the
GPCR expression profiles of BMM and TEPM to the
remaining panel of cell types, and in doing so, identified
67 GPCRs that were detectably expressed either constitu-
tively or in an LPS-induced manner in these primary mac-
rophage populations [see additional file 1].
In order to identify GPCRs that were very highly expressed
by BMM and/or TEPM, we set an arbitrary cut-off in which
normalised expression in either BMM or TEPM was at
least 10-fold greater than the median normalised expres-
sion across all cell types. Using this very strict filtering
approach, we identified 33 GPCRs that were enriched in
BMM and/or TEPM as compared to the median normal-
ised expression (Table 1 and 2). This, of course, does not
mean that such genes are exclusively expressed by macro-
phages. For example, Gpr85 was highly expressed in sev-
eral macrophage populations and was further up-
regulated by LPS, but was also expressed in several regions
of the brain (Figure 1a). Nevertheless, included in this set
were GPCRs such as Emr1 (F4/80), C3aR, C5aR, Ccrl2 and
Ccr2 that are known to be either macrophage-specific or
highly expressed by macrophages [8-12], thus validating
our approach. Also included in this list were a number of
GPCRs (e.g. Edg5, P2ry2 and 6) that have not previously
been reported to have a macrophage-restricted expression
pattern (Table 2). As demonstrated in figure 1b, P2ry6
expression was strikingly restricted to macrophages and
two cell types closely related to macrophages (osteoclasts
and dendritic cells), whilst a number of other P2Y family
receptors were also highly expressed by this lineage (Table
2). Consistent with this conclusion, we recently observed
a macrophage-restricted expression pattern for P2ry6
mRNA in a much more limited analysis across seven dif-
ferent cell populations [2]. Gpr84 expression was also
largely restricted to macrophage populations and granulo-
cytes (Figure 1c).
Differential GPCR expression in distinct macrophage 
populations
We also searched for GPCRs with differing expression pat-
terns in non-inflammatory macrophages (BMM) versus
inflammatory macrophages (TEPM). Those GPCRs that
were highly expressed by BMM, but not TEPM, included
Ebi2, Calcrl, Ccr2 and 5, Cxcr3, Cx3cr1 and Gpr84, whilst
TEPM expressed much higher levels of Cxcr4, Gpr35,
P2ry1, Ccr1, Cd97, Ccrl2 and Gprc5b (Table 2). As an
example, figure 2a and 2b demonstrate the selective
expression of Calcrl and Gprc5b in BMM and TEPM,
Table 1: Summary of GPCRs expressed by macrophages.
Highly Expressed
BMM TEPM
22
10 only enriched in BMM
23
11 only enriched in TEPM
12 regulated in both BMM and TEPM
LPS Regulation
Induced
BMM TEPM
27
14 only regulated in BMM
16
3 only regulated in TEPM
13 regulated in both BMM and TEPM
Repressed
BMM TEPM
19
9 regulated only in BMM
18
8 regulated only in TEPM
10 regulated in both BMM and TEPM
Summary of GPCRs highly expressed or regulated in macrophages as 
assessed by micro-array analysis.Page 2 of 13
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course, reflect the differential growth state of the cells;
BMM are cycling cells whilst TEPM are post-proliferative.
Indeed, many of these genes showed similar expression
profiles in BMM and RAW264 cells, both of which are
proliferating macrophage populations. Nonetheless, there
were also GPCRs that had distinct expression levels in
BMM versus TEPM, as well as BMM versus RAW264. It is
Table 2: Macrophage-enriched GPCRs.
Relative Normalised Expression
Receptor Class Accession Number Gene Name BMM TEPM RAW264.7
Enriched in both BMM and TEPM
Class A
NM_009779 C3ar1 1361.1 683.6 58.3
NM_007577 C5r1 822.6 25.6 10.5
NM_183168 P2ry6 434.0 94.0 196.4
NM_009917 Ccr5 214.2 20.5 0.6
NM_021476 Cysltr1 208.9 12.5 40.6
NM_004230 Edg5 30.2 69.3 6.6
NM_008967 Ptgir 24.7 72.1 1.7
NM_009924 Cnr2 14.2 27.2 6.7
NM_009912 Ccr1 14.1 235.1 16.3
NM_145700 Ccrl1 11.1 26.6 12.7
NM_008964 Ptger2 10.7 34.4 0.8
Class B
NM_010130 Emr1 190 22.2 28.3
Enriched in BMM
Class A
NM_183031 Ebi2 113.5 6.1 245.2
NM_009915 Ccr2 92.1 1.2 1.3
NM_030720 Gpr84 77.5 0.6 2.7
NM_008042 Fprl1 32.0 1.0 0.8
NM_008152 Gpr65 29.3 9 6.6
NM_009910 Cxcr3 26.3 1.1 7.6
NM_007420 Adrb2 22.1 1.3 9.3
NM_145066 Gpr85 13.7 1.7 7.6
NM_009987 Cx3cr1 11.3 0.7 61.4
Class B
NM_018782 Calcrl 45.6 1.1 6.1
Enriched in TEPM
Class A NM_009911 Cxcr4 4.3 178.9 0.6
NM_017466 Ccrl2 3.1 154.9 1.1
NM_021381 Prokr1 1.0 36.6 0.7
NM_022320 Gpr35 2.5 22.0 0.4
NM_008311 Htr2b 1.1 19.9 0.5
NM_008773 P2ry2 8.5 19.2 1.5
NM_133200 P2ry14 4.0 18.4 0.4
NM_175493 Gpr68 0.9 17.9 9.3
NM_008772 P2ry1 4.4 10.6 0.6
Class B
NM_011925 Cd97 0.4 22.9 0.2
Class C
NM_022420 Gprc5b 0.6 60.6 0.6
Micro-array analysis was used to identify GPCRs that were highly enriched in primary mouse macrophages (BMM and TEPM). GPCRs identified as 
highly enriched in BMM or TEPM were defined as GPCRs where the normalised value was as least 10-fold greater and significantly different (p-value 
< 0.05, Student's two-tailed t-test) from the median expression across all cell types. GPCRs are grouped according to their class type on the basis 
of sequence similarity as previously described [65-67].Page 3 of 13
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genes in BMM versus TEPM is a reflection of the prolifera-
tive state of the cells. Examples of these include Ccr2,
Gpr84 and Fprl1 that were selectively enriched in BMM as
compared to TEPM and RAW264, whilst Gpr68 was
enriched in both TEPM and RAW264 but not BMM. Such
GPCRs may have distinct functions in macrophage differ-
entiation, recruitment or activation. Apart from our anal-
ysis of macrophage-enriched GPCRs, we also identified
several GPCRs (e.g. Gpr65, Ccr1, Ccrl1, Cnr2 and P2ry14)
that were highly expressed by multiple leukocyte popula-
tions. As an illustration, figure 2c shows the immune-
restricted expression of P2ry14.
LPS-regulated GPCR expression in mouse macrophages
LPS, the archetypal macrophage-activating stimulus that
signals via toll-like receptor (TLR) 4, regulated the expres-
sion of several GPCRs in macrophages (Table 3 and 4).
Whilst LPS is already known to regulate the expression of
many of these (e.g. Gpr109b/PUMA-G, Fpr1, Ccrl2 and
Ednrb) ([12-16], Sweet et al, unpublished data), regulated
expression of others has not been widely studied. Exam-
ples of these include Fzd1, Htr2b, Gpr84 (induced by LPS,
Table 3), and P2ry1 and 5 (repressed by LPS, Table 4). We
recently validated the LPS-mediated repression of P2ry5
mRNA expression in BMM by real time PCR [2]. Figure 3
highlights two examples of regulated GPCR expression:
Macrophage-restricted GPCRsFigure 1
Macrophage-restricted GPCRs. Micro-array analysis of Gpr85 (A), P2ry6 (B) and Gpr84 (C) mRNA expression across a 
panel of 91 murine cell types and tissues. Data points show normalised values and similar cell types are grouped according to 
bar colour; blue indicates primary macrophage cell types, purple indicates bone-related cell types, red indicates other immune 
cell types, green indicates stem cell populations, orange indicates whole tissue samples, yellow indicates neuronal and retinal 
cell types and pink indicates cell lines. Additional file 3 gives details of the 91 cell types and tissues profiled.
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Immunome Research 2008, 4:5 http://www.immunome-research.com/content/4/1/5mRNA expression of Gpr84 was induced 10-fold by LPS (6
h) in BMM and 48-fold by LPS (7 h) in TEPM (Figure 3a),
whilst P2ry1 was repressed 7-fold by LPS (6 h) in BMM
and 18-fold by LPS (7 h) in TEPM (Figure 3b).
The LPS time courses studied in BMM (2, 6 and 24 h) and
TEPM (1 and 7 h) were not identical and so it is difficult
to make definitive conclusions about non-conserved reg-
ulation by LPS in these two cell populations. Nonetheless,
we did identify genes that appeared to be differentially
regulated by LPS in BMM or TEPM at similar time points.
Gpr18, P2ry2, P2ry12 and Adrb2 were all strongly regu-
lated by LPS in BMM, but not TEPM (Table 3, 4), whilst
LPS regulated Gprc5b expression in TEPM, but not BMM
(Table 4). The effects of LPS could even be opposing in
these two cell populations; Prokr1 was induced 37-fold by
LPS in BMM (6 h), but repressed 20-fold in TEPM (7 h)
(Figure 3c). Again some of these differences may be
explained by the proliferative state of the cells; LPS triggers
growth arrest in BMM and so some of the LPS-regulated
genes unique to BMM may reflect this phenomenon. This
is clearly not the case for all genes however (e.g. P2ry14
GPCRs differentially regulated in BMM and TEPMFigure 2
GPCRs differentially regulated in BMM and TEPM. Micro-array analysis of Calcrl (A), Gprc5b (B) and P2ry14 (C) mRNA 
expression across a panel of 91 murine cell types and tissues. Data points show normalised values and similar cell types are 
grouped according to bar colour; blue indicates primary macrophage cell types, purple indicates bone-related cell types, red 
indicates other immune cell types, green indicates stem cell populations, orange indicates whole tissue samples, yellow indi-
cates neuronal and retinal cell types and pink indicates cell lines. Additional file 3 gives details of the 91 cell types and tissues 
profiled.
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Immunome Research 2008, 4:5 http://www.immunome-research.com/content/4/1/5and Prokr1), thus arguing that subtle differences in LPS
signaling pathways may exist in BMM versus TEPM.
Discussion
With an understanding of the GPCRs that are (a) highly
expressed by the mononuclear phagocyte system, (b)
selectively expressed by certain macrophage populations,
Table 3: GPCRs induced by LPS in macrophages.
Relative Normalised Expression
Receptor Class Accession Number Gene Name BMM TEPM
2 h 6 h 24 h 1 h 7 h
Induced by LPS in BMM and TEPM
Class A
NM_009630 Adora2a 1.2 28.2 3.3 4.2 52.2
NM_007413 Adora2b 27.4 190.9 17.4 3.0 3.3
NM_007719 Ccr7 1.0 5.1 1.9 0.4 2.9
NM_017466 Ccrl2 39.2 65.7 46.7 13.8 9.2
NM_010336 Edg2 7.3 5.7 0.3 1.0 10.0
NM_007904 Ednrb 6.7 2.0 10.3 0.7 5.3
NM_013521 Fpr1 5.9 120.9 23.3 1.0 21.4
NM_008042 Fprl1 3.8 41.6 28.6 3.1 570.6
NM_030701 Gpr109b 13.6 48.2 5.6 10.8 212.0
NM_030720 Gpr84 8.7 10.3 0.2 7.8 47.5
NM_145066 Gpr85 3.6 5.6 0.5 18.1 4.9
Class B
NM_018782 Calcrl 1.0 2.6 0.2 0.6 6.9
Frizzled
NM_021457 Fzd1 8.0 17.0 1.0 1.0 2.2
Induced by LPS in BMM
Class A
NM_009912 Ccr1 0.9 3.1 7.4 0.8 0.7
NM_009911 Cxcr4 0.3 0.1 7.2 0.7 0.1
NM_004230 Edg5 0.2 0.5 2.0 0.4 0.6
NM_182806 Gpr18 17.8 52.2 10.8 1.0 1.6
NM_175493 Gpr68 3.3 1.7 40.2 1.5 0.8
NM_013533 Gpr162 1.1 0.5 6.7 0.8 0.8
NM_008311 Htr2b 0.6 0.5 15.8 0.6 0.3
NM_008519 Ltb4r1 0.8 0.8 7.5 0.9 0.7
NM_008773 P2ry2 3.7 7.5 3.7 1.9 1.1
NM_021381 Prokr1 0.8 37.4 7.2 0.3 0.1
NM_008964 Ptger2 2.4 1.3 11.7 0.3 0.1
NM_008967 Ptgir 1.1 2.3 7.4 0.7 0.6
Class B
NM_139138 Emr4 1.1 2.0 1.0 1.0 0.9
NM_001081298 Lphn2 2.2 1.4 1.2 0.3 0.3
Induced by LPS in TEPM
Class A
NM_007577 C5r1 1.1 0.7 0.1 3.0 1.1
NM_007722 Cxcr7 0.5 0.5 0.5 1.0 4.0
NM_133200 P2ry14 0.7 1.7 1.4 0.8 6.7
Micro-array analysis was used to assess the gene expression profile of GPCRs upon LPS treatment in primary mouse macrophages (BMM and TEPM). 
GPCRs regulated by LPS in primary mouse macrophages were defined as those that were 2-fold or greater up-regulated at 2, 6 or 24 h LPS in BMM and/
or 1 or 7 h LPS in TEPM (and significantly different from controls, p-value < 0.05, Student's two-tailed t-test). Values shown depict gene expression 
relative to untreated control (0 h). GPCRs are grouped according to their class type on the basis of sequence similarity as previously described [65-67].Page 6 of 13
(page number not for citation purposes)
Immunome Research 2008, 4:5 http://www.immunome-research.com/content/4/1/5or (c) regulated by the pro-inflammatory stimulus LPS,
one can make some inferences about the role of specific
GPCRs in macrophage biology. One of the most obvious
findings from our analysis was that many of the P2Y
purinergic receptors, which detect purine and pyrimidine
nucleotides, were expressed in a restricted and/or regu-
lated fashion in macrophages. Mechanical stress, cellular
injury, inflammatory stimuli such as LPS, degranulation
of mast cells and hypoxia can all increase extracellular
concentrations of ATP and UTP [17-20]. Consequently,
Table 4: GPCRs repressed by LPS in macrophages.
Relative Normalised Expression
Receptor Class Accession Number Gene Name BMM TEPM
2 h 6 h 24 h 1 h 7 h
Repressed by LPS in BMM and TEPM
Class A
NM_009924 Cnr2 0.2 0.1 0.3 0.3 0.1
NM_009911 Cxcr4 0.3 0.1 7.1 0.7 0.1
NM_183031 Ebi2 0.2 0.1 0.1 0.4 0.2
NM_004230 Edg5 0.2 0.5 2.0 0.4 0.6
NM_022320 Gpr35 0.2 0.4 1.6 0.6 0.1
NM_030258 Gpr146 0.1 0.4 1.0 0.4 0.1
NM_008772 P2ry1 0.3 0.1 0.2 0.3 0.1
NM_175116 P2ry5 0.1 0.1 0.7 0.3 0.1
NM_013641 Ptger1 0.7 0.5 0.3 0.7 0.3
NM_008965 Ptger4 3.1 0.5 1.0 1.9 0.3
Repressed by LPS in BMM
Class A
NM_007420 Adrb2 0.3 0.1 0.1 1.9 0.8
NM_009779 C3ar1 0.7 0.5 0.3 0.8 0.6
NM_007577 C5r1 1.1 0.7 0.1 3.0 1.1
NM_009915 Ccr2 0.5 0.4 0.2 0.8 0.9
NM_009910 Cxcr3 0.7 0.1 0.1 1.6 0.9
NM_009987 Cx3cr1 0.5 0.1 0.1 1.0 0.7
NM_030720 Gpr84 8.3 10.0 0.2 7.7 50.0
NM_027571 P2ry12 0.5 0.1 0.2 1.0 1.0
Class B
NM_018782 Calcrl 1.0 2.6 0.2 0.6 7.1
Repressed by LPS in TEPM
Class A
NM_007719 Ccr7 1.0 5.0 1.9 0.4 2.9
NM_021381 Prokr1 0.8 33.3 7.1 0.3 0.1
NM_198168 Ppp2r5b 1.0 1.3 1.1 0.8 0.5
NM_008964 Ptger2 2.4 1.3 11.1 0.3 0.1
Class B
NM_080437 Celsr3 0.8 1.2 2.3 0.2 0.2
NM_173036 Gpr97 0.8 1.0 0.8 0.5 0.2
NM_016894 Ramp1 1.0 1.0 1.0 0.5 0.2
Class C
NM_022420 Gprc5b 1.0 1.0 1.3 0.8 0.1
Micro-array analysis was used to assess the gene expression profiles of GPCRs upon LPS treatment in primary mouse macrophages (BMM and 
TEPM). GPCRs regulated by LPS in primary mouse macrophages were defined as those that were 2-fold or greater down-regulated at 2, 6 or 24 h 
LPS in BMM and/or 1 or 7 h LPS in TEPM (and significantly different from controls, p-value < 0.05, Student's two-tailed t-test). Values shown depict 
gene expression relative to untreated control (0 h). GPCRs are grouped according to their class type on the basis of sequence similarity as 
previously described [65-67].Page 7 of 13
(page number not for citation purposes)
Immunome Research 2008, 4:5 http://www.immunome-research.com/content/4/1/5these receptors are very likely to impact upon macro-
phage-mediated inflammatory responses.
Of the P2Y family, perhaps most striking in its expression
pattern was P2ry6, which was essentially restricted to cells
of the myeloid lineage. P2ry6 mRNA levels were greatly
elevated in BMM, TEPM, RAW264 cells, microglia, osteo-
clasts and dendritic cells, compared to all other cell types
(Figure 1b). P2ry6 expression in osteoclasts, which are a
closely related lineage to macrophages, has been con-
firmed by others [21]. Whilst no previous studies have
indicated that P2ry6 expression is restricted to the mono-
cyte/macrophage lineage, there is evidence to suggest that
this receptor does regulate the function of macrophages.
UDP, which is reportedly a selective P2RY6 agonist
[22,23], triggered interleukin (IL)-8 release from the
human monocyte-like cell line, THP-1 [24]. Conversely,
the P2RY6 receptor antagonists, anthraquinone-sulfonic
acid derivative reactive blue 2 and suramin, inhibited LPS-
induced IL-8 production by THP-1 cells [24]. In microglia,
P2ry6 mRNA expression was up-regulated in response to
neuronal damage and UDP promoted phagocytosis by
microglia, thus implying a role for P2RY6 in the clearance
of damaged or dead neuronal cells [23]. Our observation
that this receptor is widely expressed in the mononuclear
phagocyte system suggests that this receptor may have a
broader function in sensing and engulfing damaged cells
throughout the body, as well as promoting pro-inflamma-
tory responses in response to LPS and/or UDP.
This laboratory previously reported that P2ry5 mRNA
expression was dramatically repressed by LPS in human
and mouse macrophages [2], a finding supported by
micro-array data presented here. This receptor was origi-
nally classified as a member of the P2Y receptor family on
the basis of sequence identity and its ability to bind the
nucleotides ATP and ADP [25]. Nucleotides failed to initi-
ate downstream signaling from this receptor however
[26], and it is therefore possible that P2RY5 acts as an
antagonist of other P2Y receptors and restricts the macro-
phage response to extracellular nucleotides. Down-regula-
tion of P2RY5 in response to a macrophage activating
stimulus such as LPS might remove this inhibitory effect,
thus allowing activated macrophages to respond to nucle-
otides. Alternatively, it is possible that the initial assign-
ment of P2RY5 as a P2 receptor was incorrect. Cross-
genome phylogenetic analysis showed that it clustered
with a heterogenous group of receptors including the pro-
tease-activated receptors, as well as lysophosphatidylcho-
line (LPA) and sphingosylphosphorylcholine (S1P)
receptors, rather than with other P2Y receptors [27]. In
this case, LPS-mediated macrophage activation would
presumably render cells unresponsive to the true ligand
for this receptor.
Emerging evidence also implicates other P2Y receptors in
macrophage-mediated inflammatory responses. For
example, extracellular ATP, an agonist of P2RY2, induced
IL-6 transcription in human monocyte-derived macro-
phages [28] and chemotaxis in human neutrophils [29],
while the P2RY1 agonist 2-methylthio ATP increased IL-6
secretion from mouse splenocytes [30]. In support of a
role for P2Y ATP receptors in macrophage function, and
consistent with our data, P2ry1 and P2ry2 mRNAs were
GPCRs regulated by LPS in macrophagesFigure 3
GPCRs regulated by LPS in macrophages. Micro-array 
expression analysis of Gpr84 (A), P2ry1 (B) and Prokr1 (C) 
mRNA in BMM and TEPM over a timecourse of 0, 2, 6, and 
24 h, and 0, 1 and 7 h, respectively. Data points show gene 
expression relative to untreated control for each cell popula-
tion (0 h).
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lated monocytes [31]. Apart from these P2Y family mem-
bers, P2RY12 was also reported to be selectively expressed
in microglia in the rat brain [32]. Our analysis also
showed that this receptor was highly enriched in micro-
glia, as well as BMM, plasmacytoid dendritic cells, osteo-
clasts and a variety of lymphoid and neural tissues [see
additional file 2a]. Finally, the P2Y-like receptor, P2ry14
(Gpr105), which is a receptor for UDP-conjugated sugars,
mediated chemotaxis of bone marrow hematopoietic
stem cells [33]. Despite the emerging literature that sug-
gests a role for P2Y receptors in macrophage-mediated
migration and inflammatory responses, a clear under-
standing of the selective agonists of these receptors and
their interplay with each other and non-P2Y receptors is
lacking. Nonetheless, our demonstration of the restricted
and regulated expression of this family in macrophages
identifies them as promising candidates for further analy-
sis.
Other GPCRs that had a relatively restricted expression
pattern and were strongly expressed by macrophages
include Edg5, Gpr85 and Gpr84 (Table 2, Figure 1a and 1c,
Additional file 2b). Edg5 is one of eight members of the
endothelial differentiation gene (EDG) family of GPCRs
that recognize LPA and S1P [34]. Several studies have doc-
umented potent effects of the EDG5 ligand, S1P on mac-
rophages. Rat alveolar macrophages responded to S1P by
producing O2- at levels comparable to those induced by
LPS or formyl-Methionyl-Leucyl-Phenylalanine [35]. Not
surprisingly, given this finding, anti-microbial effects of
S1P have been reported. In human monocyte-derived
macrophages or THP-1 cells infected with M. smegmatis or
M. tuberculosis, S1P reduced intracellular bacterial loads in
a dose-dependent manner. Similar effects of S1P were also
apparent in mice infected with M. smegmatis or M. tuber-
culosis [36]. Apart from activating anti-microbial
responses, S1P also provided a survival signal to both
mouse and human macrophage cell lines upon subse-
quent exposure to an apoptosis-inducing signal [37].
EDG1 was implicated in this response, but given the high
expression of Edg5 reported here, this receptor may also
be involved in macrophage responses to S1P.
Expression of the SREB (super conserved receptor
expressed in brain) family member Gpr85 (Sreb2) was
restricted to macrophages and neuronal tissues (Figure
1a). Whilst the expression of Gpr85 in the central nervous
system was previously reported [38-40], a function has yet
to be identified. The co-regulated expression of receptors
such as Gpr85 in neural tissues and leukocyte populations
may provide a mechanism for the neuro-immune cross-
talk that has been observed in several studies [41,42].
Gpr84 is an orphan GPCR that was strikingly restricted to
BMM and microglia in an unstimulated state (Table 2, Fig-
ure 1c) and was strongly up-regulated by LPS in both
BMM and TEPM (Figure 3a, Table 3). This up-regulation
is consistent with elevated Gpr84 expression in microglia
and tissue macrophages in an endotoxin shock model
[43]. Microglia also expressed high levels of Gpr84 in the
experimental autoimmune encephalomyelitis model of
multiple sclerosis [43]. These data imply that GPR84 has
a role in neuroinflammation, but the exact function is dif-
ficult to predict without any knowledge of a ligand. None-
theless, given the highly restricted expression pattern of
Gpr84 mRNA, antibodies against this receptor may pro-
vide useful tools for tracking macrophage populations in
vivo.
As with Gpr84, mRNA for several other GPCRs, particu-
larly chemokine receptors, were differentially expressed
between various unstimulated macrophage populations.
TEPM expressed elevated levels of mRNA for Cxcr4, Ccr1,
Ccrl2, whilst BMM expressed higher levels of Ccr2, Cx3cr1
and Cxcr3. The fractalkine receptor CX3CR1 has been
identified as a marker of patrolling monocytes that survey
the endothelial surface [44] and its down-regulation on
macrophages that have already trafficked to an inflamma-
tory site is not surprising. Conversely, CXCR4 has a well-
characterized function in targeting leukocytes and their
progenitors away from the circulation [45], consistent
with its enhanced expression in TEPM. Apart from chem-
okine receptors, the expression of a number of other
GPCRs was different between BMM and TEPM. For exam-
ple, the thrombin-related receptor, Ebi2 [46], was strongly
expressed in BMM but not TEPM, whilst Gprc5b was
enriched in TEPM but not BMM. Such differences are
likely to contribute to functional divergence between tis-
sue macrophage and inflammatory macrophage popula-
tions.
Many of the GPCRs that were highly expressed by macro-
phages in an unstimulated state (described above), were
also regulated by LPS. Several other GPCRs were weakly
expressed by unstimulated macrophages but were
strongly regulated by LPS. One such example was the friz-
zled family member, Fzd1. Frizzleds (Fzd) represent the
cell membrane receptors for a family of secreted glycopro-
teins called wingless-related proteins (WNTs). Wnts play
essential roles in development, including cell fate deter-
mination, adhesion, polarity, migration and proliferation
[47-50]. The WNT family has also been implicated in
immune regulation. For example, the WNT family mem-
ber, WNTD, acted as a negative feedback regulator of Toll
signaling in Drosophila [51]. In human macrophages,
WNT5A expression was up-regulated by TLR ligands, as
well as challenge with M. tuberculosis and M. avium, and
the WNT5A/Frizzled-5 (FZD5) pathway promoted IL-12Page 9 of 13
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[52]. The striking up-regulation of Fzd1 in BMM (17-fold
at 6 h LPS) implies that this FZD family member shares
similar functions in regulating macrophage inflammatory
responses.
We also identified several GPCRs that were differentially
regulated by LPS in BMM and TEPM. In BMM, Prokr1 was
transiently induced by LPS (37-fold at 6 h) but repressed
in TEPM (20-fold at 7 h). PROKR1 is a receptor for proki-
neticin 1 (PK1), a peptide that regulates monocyte differ-
entiation, as well as macrophage activation and
migration. PK1 triggered the differentiation of both
murine and human bone marrow progenitor cells into the
monocyte/macrophage lineage [53], and reprogrammed
the response of human monocytes to LPS by amplifying
IL-12 and tumor necrosis factor alpha (TNF) production,
but inhibiting IL-10 release [53]. The differential regula-
tion of Prokr1 by LPS in BMM versus TEPM implies that
this receptor has distinct functions during activation of tis-
sue versus inflammatory macrophage populations.
Gpr18 was induced 52-fold in BMM following 6 h LPS
exposure, while it remained unchanged in TEPM. This
receptor was also highly expressed in other immune cell
populations including B cells, T cells and DC cells [see
additional file 2c]. N-arachidonylglycine (NAGly), a con-
jugate of arachidonic acid and glycine, is an endogenous
ligand for GPR18 [54] that was reported to suppress
inflammatory pain and have analgesic properties [55,56].
Given the potent regulation of Gpr18 expression in BMM
by LPS, NAGly is also likely to regulate macrophage func-
tion. The adenosine receptor, Adora2b was also strongly
induced by LPS in BMM (191-fold at 6 h) yet was only
modestly regulated (3-fold at 7 h) in TEPM. Adenosine-
mediated activation of this receptor augmented IL-10 pro-
duction by RAW264 cells in response to LPS [57]. In con-
trast, adenosine attenuated LPS-induced production of
the pro-inflammatory cytokines TNF [58-61] and IL-12
[60,62] in mouse and human macrophages. Inducible
Adora2b expression may therefore contribute to feedback
regulation of macrophage inflammatory responses.
Conclusion
In this study, we have documented several GPCRs that are
detectably expressed in primary mouse macrophages
(BMM, TEPM), enriched in either or both BMM and
TEPM, or regulated in activated macrophages (LPS-stimu-
lated BMM and/or TEPM). For some of these genes, con-
stitutive or regulated expression in macrophages has not
previously been described. Future studies on such GPCRs
and their agonists are likely to provide important insights
into macrophage biology, as well as novel inflammatory
pathways which could be future targets for drug discovery.
Methods
Cell culture and reagents
All cell lines and tissues were sourced from 8–10 week old
male C57Bl/6 mice, with the exception of female-specific
organs, which were sourced from female mice. All proce-
dures were carried out in accordance with local guidelines
for animal research. For female tissues, material was
pooled from three females and for each female an average
four embryos resulting in four umbilical cords and pla-
centas were obtained. For other tissues, material was
derived from a pool of three males. Biological replicates
were defined as independent RNA preparations from
independent pools of mice. Technical replicates were
defined as independent amplifications from the same
RNA sample. The full list of cell lines and tissues profiled,
as well as further details on biological versus technical
replication, is provided in additional file 3 (key to figures
1, 2 and additional file 2).
Mouse BMM were prepared from bone marrow cells from
femurs of adult C57Bl/6 mice by culturing for 7 days in
complete medium (RPMI containing 10% FCS, 20 U/ml
penicillin, 20 μg/ml streptomycin and 2 mM L-glutamine
(Invitrogen) in the presence of 10 000 U/ml CSF-1 (a gift
from Chiron, Emeryville, CA) on bacteriological plastic
plates. On day 7, BMM were treated with 10 ng/mL Salmo-
nella minnesota LPS (Re595 mutant, Sigma) for 2, 6 or 24
h, and RNA was extracted. To generate TEPM, cells were
harvested from the peritoneal cavity of C57Bl/6 mice 3 d
after i.p. administration of 3% thioglycollate broth
(Difco). Cells were then plated onto tissue culture plastic
for 2 h, after which time non-adherent cells were removed
by washing with PBS. Adherent TEPM were then treated
with LPS for 1 or 7 h, or were left untreated, and RNA was
extracted. Microglia were generated from cultures of
mixed cortical cells. After 10 d culture, microglia were sep-
arated from astroglia by shaking on an orbital shaker (180
rpm, 20 min, 37°C) in the presence of 12 mM lidocaine
(Sigma).
RNA and cDNA preparation
RNA extraction from mammalian cells or tissues was per-
formed using RNeasy kits (Qiagen) or the standard Trizol
protocol. If tissue amounts were more than 50 mg per
mouse when dissected, tissues were pulverized while fro-
zen. RNA was prepared separately for every mouse in
order to identify samples with potentially degraded RNA.
Trizol-extracted RNA was purified with a Qiagen RNeasy
column. For BMM, osteoblasts and osteoclasts contami-
nating genomic DNA was removed during the RNeasy
cleanup using DNaseI (Qiagen). The integrity and concen-
tration of RNA was determined via microfluidic analysis
on a bio-analyser (Agilent Technologies) or by analysis on
a BioRad Experion (BioRad). Pooling occurred at the RNA
level. For samples containing more than two μg total RNAPage 10 of 13
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fication was performed using two μg total RNA. For
pooled samples containing less than two μg total RNA,
100 ng total RNA (or 50 ng for thymocyte SP CD8+) was
used in a standard Affymetrix double amplification proto-
col. The starting quantity of RNA for specific tissues is
included in additional file 3.
Microarray analysis
Standard Affymetrix protocols were used to process
Affymetrix MOE430_2 microarrays. All CEL file images
were processed as a single group using gcRMA [63,64],
after which the data for each gene was rescaled using per-
gene normalisation to the median (for tissue specificity
analysis) or per-gene normalisation to untreated control
samples (for analysis of BMM and TEPM gene regulation
by LPS). The microarray data described have been depos-
ited in NCBIs Gene Expression Omnibus [5] and are
accessible through GEO Series accession number
GSE10246. GPCRs identified as highly enriched in BMM
or TEPM were defined as transcripts where the normalised
expression value was as least 10-fold greater in BMM/
TEPM when compared to the median expression across all
cell types and where BMM/TEPM expression significantly
deviated from this median value (p-value < 0.05, student's
two-tailed t-test). GPCRs regulated by LPS in primary
mouse macrophages were defined as those whose normal-
ised expression values were two-fold or greater up- or
down-regulated at any point in the time course (2, 6 or 24
h LPS in BMM and/or 1 or 7 h LPS in TEPM) compared to
the unstimulated state (0 LPS). LPS regulated genes were
also filtered on the basis of statistical significance (p-value
< 0.05, student's two-tailed t-test). All statistical testing
was performed using the GeneSpring GX software, with
the cross-gene error model function enabled.
Abbreviations
BMM: bone marrow-derived macrophage; EDG: endothe-
lial differentiation gene; Fzd: Frizzled; GPCR: G Protein-
Coupled Receptor; IL: interleukin; LPA: lysophosphatidyl-
choline; LPS: lipopolysaccharide; NAGly: N-arachido-
nylglycine; P2Y: purinergic receptor family Y; PK1:
prokineticin 1; S1P: sphingosylphosphorylcholine; SREB:
super conserved receptor expressed in brain; TEPM: thi-
oglycollate-elicited peritoneal macrophage; TLR: Toll-like
Receptor; TNF: tumor necrosis factor alpha; Wnt: Wing-
less-related protein.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JL carried out filtering and analysis of the GNF microarray
expression data and drafted the manuscript. KS carried out
the extraction of the microarray expression data and par-
ticipated in the design of the study and review of the man-
uscript. AS, JZ and JW generated GNF microarray
expression data. KS and CG purified cell populations and
generated RNA for microarray analysis. DH and SK
assisted in the review and editing of the manuscript. MS
participated in the design of the study and drafting of the
manuscript. All authors read and approved the final man-
uscript.
Additional material
Acknowledgements
This work was supported by NHMRC Dora Lush and Queensland Govern-
ment Smart State Fellowships to JL. A portion of this work was supported 
by the Novartis Research Foundation.
References
1. McKnight AJ, Macfarlane AJ, Dri P, Turley L, Willis AC, Gordon S:
Molecular cloning of F4/80, a murine macrophage-restricted
cell surface glycoprotein with homology to the G-protein-
linked transmembrane 7 hormone receptor family.  J Biol
Chem 1996, 271(1):486-489.
2. Lattin J, Zidar DA, Schroder K, Kellie S, Hume DA, Sweet MJ: G-pro-
tein-coupled receptor expression, function, and signaling in
macrophages.  J Leukoc Biol 2007, 82(1):16-32.
3. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J,
Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch
JB: A gene atlas of the mouse and human protein-encoding
transcriptomes.  Proc Natl Acad Sci U S A 2004, 101(16):6062-6067.
Additional file 1
GPCR expression in Mouse Macrophages. The table lists all GPCRs 
expressed in mouse macrophages.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
7580-4-5-S1.doc]
Additional file 2
Macrophage-restricted GPCRs. The data provided demonstrates the mac-
rophage-restricted expression of P2ry12, Edg5 and Gpr18 mRNA. 
Micro-array analysis of P2ry12 (A), Edg5 (B) and Gpr18 (C) mRNA 
expression across a panel of 91 murine cell types and tissues. Data points 
show normalised values and similar cell types are grouped according to bar 
colour; blue indicates primary macrophage cell types, purple indicates 
bone-related cell types, red indicates other immune cell types, green indi-
cates stem cell populations, orange indicates whole tissue samples, yellow 
indicates neuronal and retinal cell types and pink indicates cell lines. 
Additional file 3 gives details of the 91 cell types and tissues profiled.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
7580-4-5-S2.eps]
Additional file 3
Cell panel sample types (legend key for figure 1 and 2 and additional file 
1). The table provides a full list of the cell lines and tissues profiled in the 
micro-array analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-
7580-4-5-S3.doc]Page 11 of 13
(page number not for citation purposes)
Immunome Research 2008, 4:5 http://www.immunome-research.com/content/4/1/54. Genomics Institute of the Novartis Research Foundation SA:
Genomics Institute of the Novartis Research Foundation,
[http://symatlas.gnf.org/SymAtlas].  .
5. NCBIs Gene Expression Omnibus : NCBIs Gene Expression
Omnibus, [http://www.ncbi.nlm.nih.gov/geo/].  .
6. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP,
Spedding M, Harmar AJ: International Union of Pharmacology.
XLVI. G protein-coupled receptor list.  Pharmacol Rev 2005,
57(2):279-288.
7. International Union of Basic and Clinical Pharmacology GPCRRFF:
International Union of Basic and Clinical Pharmacology,
[http://www.iuphar-db.org/GPCR/ReceptorFamiliesFor-
ward].  .
8. Austyn JM, Gordon S: F4/80, a monoclonal antibody directed
specifically against the mouse macrophage.  Eur J Immunol
1981, 11(10):805-815.
9. Hirsch S, Austyn JM, Gordon S: Expression of the macrophage-
specific antigen F4/80 during differentiation of mouse bone
marrow cells in culture.  J Exp Med 1981, 154(3):713-725.
10. Chenoweth DE, Goodman MG, Weigle WO: Demonstration of a
specific receptor for human C5a anaphylatoxin on murine
macrophages.  J Exp Med 1982, 156(1):68-78.
11. Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, Fontaine M, Mor-
gan BP: The receptor for complement anaphylatoxin C3a is
expressed by myeloid cells and nonmyeloid cells in inflamed
human central nervous system: analysis in multiple sclerosis
and bacterial meningitis.  J Immunol 1998, 160(7):3543-3554.
12. Shimada T, Matsumoto M, Tatsumi Y, Kanamaru A, Akira S: A novel
lipopolysaccharide inducible C-C chemokine receptor
related gene in murine macrophages.  FEBS Lett 1998,
425(3):490-494.
13. Katsuyama M, Ikegami R, Karahashi H, Amano F, Sugimoto Y,
Ichikawa A: Characterization of the LPS-stimulated expres-
sion of EP2 and EP4 prostaglandin E receptors in mouse
macrophage-like cell line, J774.1.  Biochem Biophys Res Commun
1998, 251(3):727-731.
14. Mandal P, Novotny M, Hamilton TA: Lipopolysaccharide induces
formyl peptide receptor 1 gene expression in macrophages
and neutrophils via transcriptional and posttranscriptional
mechanisms.  J Immunol 2005, 175(9):6085-6091.
15. Schaub A, Futterer A, Pfeffer K: PUMA-G, an IFN-gamma-induc-
ible gene in macrophages is a novel member of the seven
transmembrane spanning receptor superfamily.  Eur J Immunol
2001, 31(12):3714-3725.
16. Wahl JR, Goetsch NJ, Young HJ, Van Maanen RJ, Johnson JD, Pea AS,
Brittingham A: Murine macrophages produce endothelin-1
after microbial stimulation.  Exp Biol Med (Maywood) 2005,
230(9):652-658.
17. Bergfeld GR, Forrester T: Release of ATP from human erythro-
cytes in response to a brief period of hypoxia and hypercap-
nia.  Cardiovasc Res 1992, 26(1):40-47.
18. Bodin P, Burnstock G: Synergistic effect of acute hypoxia on
flow-induced release of ATP from cultured endothelial cells.
Experientia 1995, 51(3):256-259.
19. Bodin P, Burnstock G: Increased release of ATP from endothe-
lial cells during acute inflammation.  Inflamm Res 1998,
47(8):351-354.
20. Detwiler TC, Feinman RD: Kinetics of the thrombin-induced
release of adenosine triphosphate by platelets. Comparison
with release of calcium.  Biochemistry 1973, 12(13):2462-2468.
21. Korcok J, Raimundo LN, Du X, Sims SM, Dixon SJ: P2Y6 nucleotide
receptors activate NF-kappaB and increase survival of oste-
oclasts.  J Biol Chem 2005, 280(17):16909-16915.
22. Communi D, Parmentier M, Boeynaems JM: Cloning, functional
expression and tissue distribution of the human P2Y6 recep-
tor.  Biochem Biophys Res Commun 1996, 222(2):303-308.
23. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa
K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K: UDP acting
at P2Y6 receptors is a mediator of microglial phagocytosis.
Nature 2007, 446(7139):1091-1095.
24. Warny M, Aboudola S, Robson SC, Sevigny J, Communi D, Soltoff SP,
Kelly CP: P2Y(6) nucleotide receptor mediates monocyte
interleukin-8 production in response to UDP or lipopolysac-
charide.  J Biol Chem 2001, 276(28):26051-26056.
25. Webb TE, Kaplan MG, Barnard EA: Identification of 6H1 as a P2Y
purinoceptor: P2Y5.  Biochem Biophys Res Commun 1996,
219(1):105-110.
26. Li Q, Schachter JB, Harden TK, Nicholas RA: The 6H1 orphan
receptor, claimed to be the p2y5 receptor, does not mediate
nucleotide-promoted second messenger responses.  Biochem
Biophys Res Commun 1997, 236(2):455-460.
27. Metpally RP, Sowdhamini R: Cross genome phylogenetic analysis
of human and Drosophila G protein-coupled receptors:
application to functional annotation of orphan receptors.
BMC Genomics 2005, 6:106.
28. Hanley PJ, Musset B, Renigunta V, Limberg SH, Dalpke AH, Sus R,
Heeg KM, Preisig-Muller R, Daut J: Extracellular ATP induces
oscillations of intracellular Ca2+ and membrane potential
and promotes transcription of IL-6 in macrophages.  Proc Natl
Acad Sci U S A 2004, 101(25):9479-9484.
29. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A,
Nizet V, Insel PA, Junger WG: ATP release guides neutrophil
chemotaxis via P2Y2 and A3 receptors.  Science 2006,
314(5806):1792-1795.
30. Straub RH, Pongratz G, Gunzler C, Michna A, Baier S, Kees F, Falk W,
Scholmerich J: Immunoregulation of IL-6 secretion by endog-
enous and exogenous adenosine and by exogenous puriner-
gic agonists in splenic tissue slices.  J Neuroimmunol 2002, 125(1-
2):73-81.
31. Guerra AN, Fisette PL, Pfeiffer ZA, Quinchia-Rios BH, Prabhu U, Aga
M, Denlinger LC, Guadarrama AG, Abozeid S, Sommer JA, Proctor
RA, Bertics PJ: Purinergic receptor regulation of LPS-induced
signaling and pathophysiology.  J Endotoxin Res 2003,
9(4):256-263.
32. Sasaki Y, Hoshi M, Akazawa C, Nakamura Y, Tsuzuki H, Inoue K, Koh-
saka S: Selective expression of Gi/o-coupled ATP receptor
P2Y12 in microglia in rat brain.  Glia 2003, 44(3):242-250.
33. Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y,
Olszak I, Dombkowski D, Olson DP, Hancock J, Choi PS, Haber DA,
Luster AD, Scadden DT: P2Y-like receptor, GPR105 (P2Y14),
identifies and mediates chemotaxis of bone-marrow hemat-
opoietic stem cells.  Genes Dev 2003, 17(13):1592-1604.
34. Takuwa Y, Takuwa N, Sugimoto N: The Edg family G protein-
coupled receptors for lysophospholipids: their signaling
properties and biological activities.  J Biochem (Tokyo) 2002,
131(6):767-771.
35. Hornuss C, Hammermann R, Fuhrmann M, Juergens UR, Racke K:
Human and rat alveolar macrophages express multiple EDG
receptors.  Eur J Pharmacol 2001, 429(1-3):303-308.
36. Garg SK, Volpe E, Palmieri G, Mattei M, Galati D, Martino A, Piccioni
MS, Valente E, Bonanno E, De Vito P, Baldini PM, Spagnoli LG, Colizzi
V, Fraziano M: Sphingosine 1-phosphate induces antimicrobial
activity both in vitro and in vivo.  J Infect Dis 2004,
189(11):2129-2138.
37. Weigert A, Johann AM, von Knethen A, Schmidt H, Geisslinger G,
Brune B: Apoptotic cells promote macrophage survival by
releasing the antiapoptotic mediator sphingosine-1-phos-
phate.  Blood 2006, 108(5):1635-1642.
38. Hellebrand S, Schaller HC, Wittenberger T: The brain-specific G-
protein coupled receptor GPR85 with identical protein
sequence in man and mouse maps to human chromosome
7q31.  Biochim Biophys Acta 2000, 1493(1-2):269-272.
39. Hellebrand S, Wittenberger T, Schaller HC, Hermans-Borgmeyer I:
Gpr85, a novel member of the G-protein coupled receptor
family, prominently expressed in the developing mouse cer-
ebral cortex.  Brain Res Gene Expr Patterns 2001, 1(1):13-16.
40. Matsumoto M, Beltaifa S, Weickert CS, Herman MM, Hyde TM, Saun-
ders RC, Lipska BK, Weinberger DR, Kleinman JE: A conserved
mRNA expression profile of SREB2 (GPR85) in adult human,
monkey, and rat forebrain.  Brain Res Mol Brain Res 2005,
138(1):58-69.
41. Salzet M: Invertebrate molecular neuroimmune processes.
Brain Res Brain Res Rev 2000, 34(1-2):69-79.
42. Ransohoff RM, Liu L, Cardona AE: Chemokines and chemokine
receptors: multipurpose players in neuroinflammation.  Int
Rev Neurobiol 2007, 82:187-204.
43. Bouchard C, Page J, Bedard A, Tremblay P, Vallieres L: G protein-
coupled receptor 84, a microglia-associated protein
expressed in neuroinflammatory conditions.  Glia 2007,
55(8):790-800.Page 12 of 13
(page number not for citation purposes)
Immunome Research 2008, 4:5 http://www.immunome-research.com/content/4/1/544. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, Sarnacki
S, Cumano A, Lauvau G, Geissmann F: Monitoring of blood vessels
and tissues by a population of monocytes with patrolling
behavior.  Science 2007, 317(5838):666-670.
45. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf
DJ, Zhang J, Ratajczak J, Ratajczak MZ: CXCR4-SDF-1 signalling,
locomotion, chemotaxis and adhesion.  J Mol Histol 2004,
35(3):233-245.
46. Birkenbach M, Josefsen K, Yalamanchili R, Lenoir G, Kieff E: Epstein-
Barr virus-induced genes: first lymphocyte-specific G pro-
tein-coupled peptide receptors.  J Virol 1993, 67(4):2209-2220.
47. Clevers H: Wnt/beta-catenin signaling in development and
disease.  Cell 2006, 127(3):469-480.
48. Cohen SM, Di Nardo S: Wingless: from embryo to adult.  Trends
Genet 1993, 9(6):189-192.
49. Dierick H, Bejsovec A: Cellular mechanisms of wingless/Wnt
signal transduction.  Curr Top Dev Biol 1999, 43:153-190.
50. Klingensmith J, Nusse R: Signaling by wingless in Drosophila.
Dev Biol 1994, 166(2):396-414.
51. Gordon MD, Dionne MS, Schneider DS, Nusse R: WntD is a feed-
back inhibitor of Dorsal/NF-kappaB in Drosophila develop-
ment and immunity.  Nature 2005, 437(7059):746-749.
52. Blumenthal A, Ehlers S, Lauber J, Buer J, Lange C, Goldmann T, Heine
H, Brandt E, Reiling N: The Wingless homolog WNT5A and its
receptor Frizzled-5 regulate inflammatory responses of
human mononuclear cells induced by microbial stimulation.
Blood 2006, 108(3):965-973.
53. Dorsch M, Qiu Y, Soler D, Frank N, Duong T, Goodearl A, O'Neil S,
Lora J, Fraser CC: PK1/EG-VEGF induces monocyte differenti-
ation and activation.  J Leukoc Biol 2005, 78(2):426-434.
54. Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, Yas-
ukawa M: Identification of N-arachidonylglycine as the endog-
enous ligand for orphan G-protein-coupled receptor GPR18.
Biochem Biophys Res Commun 2006, 347(3):827-832.
55. Burstein SH, Rossetti RG, Yagen B, Zurier RB: Oxidative metabo-
lism of anandamide.  Prostaglandins Other Lipid Mediat 2000, 61(1-
2):29-41.
56. Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE,
Sivakumar R, Coop A, Maeda DY, De Petrocellis L, Burstein S, Di
Marzo V, Walker JM: Identification of a new class of molecules,
the arachidonyl amino acids, and characterization of one
member that inhibits pain.  J Biol Chem 2001,
276(46):42639-42644.
57. Nemeth ZH, Lutz CS, Csoka B, Deitch EA, Leibovich SJ, Gause WC,
Tone M, Pacher P, Vizi ES, Hasko G: Adenosine augments IL-10
production by macrophages through an A2B receptor-medi-
ated posttranscriptional mechanism.  J Immunol 2005,
175(12):8260-8270.
58. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA: Differ-
ential regulatory effects of adenosine on cytokine release by
activated human monocytes.  J Immunol 1994,
153(9):4159-4168.
59. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES: Ade-
nosine receptor agonists differentially regulate IL-10, TNF-
alpha, and nitric oxide production in RAW 264.7 macro-
phages and in endotoxemic mice.  J Immunol 1996,
157(10):4634-4640.
60. Link AA, Kino T, Worth JA, McGuire JL, Crane ML, Chrousos GP,
Wilder RL, Elenkov IJ: Ligand-activation of the adenosine A2a
receptors inhibits IL-12 production by human monocytes.  J
Immunol 2000, 164(1):436-442.
61. McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Brad-
shaw M, De M, Borcherding DR, Edwards CK 3rd: Activation of
adenosine A3 receptors on macrophages inhibits tumor
necrosis factor-alpha.  Eur J Pharmacol 1996, 310(2-3):209-216.
62. Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley
JG, Marton A, Szabo C: Adenosine inhibits IL-12 and TNF-
[alpha] production via adenosine A2a receptor-dependent
and independent mechanisms.  Faseb J 2000, 14(13):2065-2074.
63. Wu Z, Irizarry RA: Stochastic models inspired by hybridization
theory for short oligonucleotide arrays.  J Comput Biol 2005,
12(6):882-893.
64. Zhijin Wu RAI Robert Gentleman,, Francisco Martinez-Murillo FS: A
Model Based Background Adjustment for Oligonucleotide
Expression Arrays.  Johns Hopkins University, Dept of Biostatistics
Working Papers 2004.
65. Flower DR: Modelling G-protein-coupled receptors for drug
design.  Biochim Biophys Acta 1999, 1422(3):207-234.
66. Gether U, Kobilka BK: G protein-coupled receptors. II. Mecha-
nism of agonist activation.  J Biol Chem 1998,
273(29):17979-17982.
67. Pierce KL, Premont RT, Lefkowitz RJ: Seven-transmembrane
receptors.  Nat Rev Mol Cell Biol 2002, 3(9):639-650.Page 13 of 13
(page number not for citation purposes)
